Abstract
The preoperative, or, as it is often called, neoadjuvant chemotherapy (NAPCT) of operable breast cancer (the breast cancer) with affected regional lymph nodes has in its time replaced preoperative radiotherapy, as it has a number of significant advantages over the latter. The most important advantage of NAPCT is its systemic action, which allows to “catch up” with probable distant micrometastases or circulating tumor cells, while preoperative radiotherapy has a local effect, and on the systemic level the tumor continues to develop. Despite of the fact that with operative breast cancer the time of NAPCT (before or after the operation) does not affect to the long-term results of treatment, the latter becames applicable even for operable breast cancer without affected regional lymph nodes.
Citation
Mohammad IMH. Individualization of Neoadjuvant Chemotherapy in Breast Cancer. SM J Clin Pathol. 2018; 3(1): 1013.